Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Vitrakvi (larotrectinib) for Advanced Solid Tumours with NTRK Gene Fusion

Drug Name

Vitrakvi® (larotrectinib)

Developer

Bayer and Loxo Oncology

Therapy Class

Kinase inhibitor

Current Indication

Advanced solid tumours with neurotrophic receptor tyrosine kinase gene fusion

Market Sector

Oncology

Development Status

Approved in the US
Expand

Go Top